Currently, a phase I/II trial combining anti-CTLA-4 and anti-PD-1 therapy is ongoing in patients with solid tumors or sarcomas (NCT02304458), which will provide information about the efficacy and safety of double immune-checkpoint blockade in tumor types other than melanoma. Here, PDCD1 is linked to melanoma.